An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New
An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York.
Sarah Maxwell, Audio Journal of Oncology:
“An exciting, new immunotherapy treatment for multiple myeloma, was under discussion at the 2024 American Association for Cancer Research Annual Meeting, held in San Diego. It was with a drug that targets not one but two cells to fight the disease.
The agent, linvoseltamab, is a B-cell maturation antigen-targeted, T-cell-engaging, bispecific antibody. A multi-center international study, reported at the conference that patients with relapsed or refractory multiple myeloma, had robust clinical benefit from treatment with the drug. And that included those in difficult-to-treat subgroups.
After giving his talk in San Diego, lead author Sundar Jagannath, Director of the Center of Excellence for Multiple Myeloma, at Mount Sinai in New York, gave the Audio Journal of Oncology more details on the therapeutic benefits the drug offers. He began by talking about where this new approach fits into the landscape and history of treatments for multiple myeloma:
Audio Journal of Oncology interview with: Sundar Jagannath MBBS, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York.
IN: I’ve been in the field of multiple myeloma….…
OUT: ….in New York. I’m Peter Goodwin.
15:43”
AACR Abstract Title:
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups
https://www.abstractsonline.com/pp8/#!/20272/presentation/11419
Related Episodes
More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths
An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce
Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere
An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington, CT And with: Jayesh Desai MD, Medical Oncologist,
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer
An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut